Suppr超能文献

DNA倍体作为可切除的壶腹癌的主要预后因素。

DNA ploidy as a major prognostic factor in resectable ampulla of Vater cancers.

作者信息

Shyr Y M, Su C H, Wu L H, Li A F, Chiu J H, Lui W Y

机构信息

Department of Surgery, Veterans General Hospital-Taipei, Yang Ming Medical College, Taiwan, Republic of China.

出版信息

J Surg Oncol. 1993 Aug;53(4):220-5. doi: 10.1002/jso.2930530406.

Abstract

The archival paraffin-embedded specimens from 63 ampulla of Vater cancers after pancreaticoduodenectomy between 1965 and 1991 were analyzed by flow cytometry. Of the 63 cancers, 31 (49.2%) were diploid DNA cancers and 32 (50.8%) were aneuploid. Patients with diploid DNA cancer had a median survival time of 159.0 months, and patients with aneuploid DNA cancer had 24.0 months. This difference is statistically significant (P = 0.0257). The aneuploid group did have a poorer prognosis than the diploid group. The multivariate analysis demonstrated that DNA ploidy was an independent and very important prognostic factor, even stronger than the stage and lymph node status. There was a tendency toward higher values of S-phase fraction, proliferative index, and total aneuploid DNA fraction in the shorter survival groups, but they were of no statistical significance. These data suggest that DNA ploidy appears to be the most important and the only pre-operative predictor of prognosis in resectable ampulla of Vater cancers since endoscopic biopsy is feasible.

摘要

对1965年至1991年间63例胰十二指肠切除术后的壶腹癌存档石蜡包埋标本进行了流式细胞术分析。在这63例癌症中,31例(49.2%)为二倍体DNA癌,32例(50.8%)为非整倍体癌。二倍体DNA癌患者的中位生存时间为159.0个月,非整倍体DNA癌患者为24.0个月。这种差异具有统计学意义(P = 0.0257)。非整倍体组的预后确实比二倍体组差。多因素分析表明,DNA倍性是一个独立且非常重要的预后因素,甚至比分期和淋巴结状态更强。生存期较短的组中S期分数、增殖指数和总非整倍体DNA分数有升高趋势,但无统计学意义。这些数据表明,由于内镜活检可行,DNA倍性似乎是可切除壶腹癌最重要且唯一的术前预后预测指标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验